Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 35Recruiting 34Completed 24Terminated 16Unknown 13Not yet recruiting 12Withdrawn 11Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 10Cisplatin 7Bevacizumab 7pembrolizumab 6Radiosurgery 6Oxaliplatin 5Nivolumab 5Irinotecan 5Fluorouracil 5Everolimus 5Capecitabine 5Biopsy 5venetoclax 4fludarabine 4S 1 (combination) 4Prednisone 4Leucovorin 4Gemcitabine 4Etoposide 4Drug Therapy 4Doxorubicin 4Azacitidine 4fludarabine phosphate 3Vincristine 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × OTHER × daratumumab × Clear all
NCT06348147 2026-05-04

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

UNC Lineberger Comprehensive Cancer Center

Phase 2 Suspended
39 enrolled
Plasma cell

Multiple Myeloma

NCT04661137 2026-02-10

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Hackensack Meridian Health

Phase 2 Suspended
96 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡